Literature DB >> 9605190

Immunohistochemical detection of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in formalin-fixed, paraffin-embedded astrocytomas.

R E McLendon1, L Cleveland, C Pegram, S H Bigner, D D Bigner, H S Friedman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9605190

Source DB:  PubMed          Journal:  Lab Invest        ISSN： 0023-6837            Impact factor:   5.662


× No keyword cloud information.
  18 in total

1.  Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.

Authors:  Ian F Pollack; Ronald L Hamilton; Robert W Sobol; Marina N Nikiforova; Yuri E Nikiforov; Maureen A Lyons-Weiler; William A LaFramboise; Peter C Burger; Daniel J Brat; Marc K Rosenblum; Floyd H Gilles; Allan J Yates; Tianni Zhou; Kenneth J Cohen; Jonathan L Finlay; Regina I Jakacki
Journal:  Pediatr Blood Cancer       Date:  2010-12-01       Impact factor: 3.167

2.  Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.

Authors:  Jill A Maxwell; Stewart P Johnson; Roger E McLendon; David W Lister; Krystle S Horne; Ahmed Rasheed; Jennifer A Quinn; Francis Ali-Osman; Allan H Friedman; Paul L Modrich; Darell D Bigner; Henry S Friedman
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

3.  MGMT immunohistochemistry in pituitary tumors: controversies with clinical implications.

Authors:  George Kontogeorgos; Eleni Thodou; Mary Koutourousiou; Gregory Kaltsas; Andreas Seretis
Journal:  Pituitary       Date:  2019-12       Impact factor: 4.107

4.  Immunohistochemical study for O6-methylguanine-DNA methyltransferase in the non-neoplastic and neoplastic components of gliomas.

Authors:  Satoshi Nakasu; Tadateru Fukami; Kazumi Baba; Masayuki Matsuda
Journal:  J Neurooncol       Date:  2004-12       Impact factor: 4.130

5.  Spontaneous hepatocellular carcinoma is reduced in transgenic mice overexpressing human O6- methylguanine-DNA methyltransferase.

Authors:  Z Q Zhou; D Manguino; K Kewitt; G W Intano; C A McMahan; D C Herbert; M Hanes; R Reddick; Y Ikeno; C A Walter
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

6.  Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.

Authors:  David A Reardon; Annick Desjardins; James J Vredenburgh; Sith Sathornsumetee; Jeremy N Rich; Jennifer A Quinn; Theodore F Lagattuta; Merrill J Egorin; Sridharan Gururangan; Roger McLendon; James E Herndon; Allan H Friedman; August J Salvado; Henry S Friedman
Journal:  Neuro Oncol       Date:  2008-03-21       Impact factor: 12.300

7.  Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.

Authors:  Jennifer A Quinn; Sara Xiaoyin Jiang; David A Reardon; Annick Desjardins; James J Vredenburgh; Allan H Friedman; John H Sampson; Roger E McLendon; James E Herndon; Henry S Friedman
Journal:  J Neurooncol       Date:  2009-06-17       Impact factor: 4.130

8.  O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma.

Authors:  Xiaoyin Jiang; David A Reardon; Annick Desjardins; James J Vredenburgh; Jennifer A Quinn; Alan D Austin; James E Herndon; Roger E McLendon; Henry S Friedman
Journal:  J Neurooncol       Date:  2013-05-18       Impact factor: 4.130

9.  Gene expression analyses of grade II gliomas and identification of rPTPbeta/zeta as a candidate oligodendroglioma marker.

Authors:  Daniel Hägerstrand; Anja Smits; Anna Eriksson; Sunna Sigurdardottir; Tommie Olofsson; Magdalena Hartman; Monica Nistér; Hannu Kalimo; Arne Ostman
Journal:  Neuro Oncol       Date:  2007-11-14       Impact factor: 12.300

Review 10.  MGMT immunoexpression in aggressive pituitary adenoma and carcinoma.

Authors:  Queenie Lau; Bernd Scheithauer; Kalman Kovacs; Eva Horvath; Luis V Syro; Ricardo Lloyd
Journal:  Pituitary       Date:  2010-12       Impact factor: 4.107
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.